Resecting Non–Contrast-Enhancing Tumor in Glioblastoma: Mitchel Berger, MD

​In patients with newly diagnosed glioblastoma, maximal extent of surgical resection of contrast-enhancing tumor has consistently been associated with benefits to survival. However, in a practice-changing study published recently in JAMA Oncology, a team of investigators under the leadership of Mitchel Berger, MD, found that extending resection to include non–contrast-enhancing tumor as well as contrast-enhancing tumor is associated with increased survival, regardless of tumor genetic subtype. I...
Continue reading

Maximal NCE Tumor Resection Impacts Glioblastoma Survival

​In patients with newly diagnosed glioblastoma, maximal extent of surgical resection of non–contrast enhanced (NCE) tumor as well as contrast-enhanced (CE) tumor is associated with increased survival regardless of tumor subtype, according to a study recently published in JAMA Oncology.Glioblastoma subtypes are known to impact disease outcome: while the 91% of patients with glioblastoma whose tumors display isocitrate dehydrogenase gene 1 or 2­­ (IDH) wild-type mutations have a median survival of...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.